
    
      This study is a phase 1, randomized, double-blind, placebo-controlled, dose escalation trial
      of Sanaria's irradiated sporozoite vaccine (PfSPZ vaccine). The primary objective of this
      study is to determine the safety and reactogenicity of the PfSPZ Vaccine in
      malaria-experienced healthy adults. The secondary objective is to evaluate vaccine-induced
      anti-CSP antibody immune responses. The study duration shall be 34 months and subject
      participation duration shall be 15-26 months.
    
  